The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Immunotherapy Drugs for Neuroblastoma Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Immunotherapy Drugs for Neuroblastoma Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2029

Publishing Date : Jul, 2023

License Type :
 

Report Code : 1751699

No of Pages : 99

Ask Your Query

Synopsis

The global Immunotherapy Drugs for Neuroblastoma market size was valued at USD 46 million in 2022 and is forecast to a readjusted size of USD 63 million by 2029 with a CAGR of 4.4% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.

This report is a detailed and comprehensive analysis for global Immunotherapy Drugs for Neuroblastoma market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

  • Global Immunotherapy Drugs for Neuroblastoma market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
  • Global Immunotherapy Drugs for Neuroblastoma market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
  • Global Immunotherapy Drugs for Neuroblastoma market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
  • Global Immunotherapy Drugs for Neuroblastoma market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023

The Primary Objectives in This Report Are:

  • To determine the size of the total market opportunity of global and key countries
  • To assess the growth potential for Immunotherapy Drugs for Neuroblastoma
  • To forecast future growth in each product and end-use market
  • To assess competitive factors affecting the marketplace

This report profiles key players in the global Immunotherapy Drugs for Neuroblastoma market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals and Baxter Healthcare, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation

Immunotherapy Drugs for Neuroblastoma market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

  • Dinutuximab
  • Naxitamab
  • Other

Market segment by Application

  • Hospital
  • Clinic
  • Other

Major players covered

  • United Therapeutics
  • Y-mAbs Therapeutics
  • EUSA Pharma
  • ANI Pharmaceuticals
  • Baxter Healthcare
  • Ingenus Pharmaceuticals
  • Pfizer
  • Hikma Pharmaceuticals
  • Teva Pharmaceuticals

Market segment by region, regional analysis covers

  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
  • South America (Brazil, Argentina, Colombia, and Rest of South America)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Immunotherapy Drugs for Neuroblastoma product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Immunotherapy Drugs for Neuroblastoma, with price, sales, revenue and global market share of Immunotherapy Drugs for Neuroblastoma from 2018 to 2023.
Chapter 3, the Immunotherapy Drugs for Neuroblastoma competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Immunotherapy Drugs for Neuroblastoma breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Immunotherapy Drugs for Neuroblastoma market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Immunotherapy Drugs for Neuroblastoma.
Chapter 14 and 15, to describe Immunotherapy Drugs for Neuroblastoma sales channel, distributors, customers, research findings and conclusion.

Index

1 Market Overview
1.1 Product Overview and Scope of Immunotherapy Drugs for Neuroblastoma
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Dinutuximab
1.3.3 Naxitamab
1.3.4 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Other
1.5 Global Immunotherapy Drugs for Neuroblastoma Market Size & Forecast
1.5.1 Global Immunotherapy Drugs for Neuroblastoma Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity (2018-2029)
1.5.3 Global Immunotherapy Drugs for Neuroblastoma Average Price (2018-2029)
2 Manufacturers Profiles
2.1 United Therapeutics
2.1.1 United Therapeutics Details
2.1.2 United Therapeutics Major Business
2.1.3 United Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
2.1.4 United Therapeutics Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 United Therapeutics Recent Developments/Updates
2.2 Y-mAbs Therapeutics
2.2.1 Y-mAbs Therapeutics Details
2.2.2 Y-mAbs Therapeutics Major Business
2.2.3 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
2.2.4 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Y-mAbs Therapeutics Recent Developments/Updates
2.3 EUSA Pharma
2.3.1 EUSA Pharma Details
2.3.2 EUSA Pharma Major Business
2.3.3 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product and Services
2.3.4 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 EUSA Pharma Recent Developments/Updates
2.4 ANI Pharmaceuticals
2.4.1 ANI Pharmaceuticals Details
2.4.2 ANI Pharmaceuticals Major Business
2.4.3 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
2.4.4 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 ANI Pharmaceuticals Recent Developments/Updates
2.5 Baxter Healthcare
2.5.1 Baxter Healthcare Details
2.5.2 Baxter Healthcare Major Business
2.5.3 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product and Services
2.5.4 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Baxter Healthcare Recent Developments/Updates
2.6 Ingenus Pharmaceuticals
2.6.1 Ingenus Pharmaceuticals Details
2.6.2 Ingenus Pharmaceuticals Major Business
2.6.3 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
2.6.4 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Ingenus Pharmaceuticals Recent Developments/Updates
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Immunotherapy Drugs for Neuroblastoma Product and Services
2.7.4 Pfizer Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Pfizer Recent Developments/Updates
2.8 Hikma Pharmaceuticals
2.8.1 Hikma Pharmaceuticals Details
2.8.2 Hikma Pharmaceuticals Major Business
2.8.3 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
2.8.4 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Hikma Pharmaceuticals Recent Developments/Updates
2.9 Teva Pharmaceuticals
2.9.1 Teva Pharmaceuticals Details
2.9.2 Teva Pharmaceuticals Major Business
2.9.3 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
2.9.4 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Teva Pharmaceuticals Recent Developments/Updates
3 Competitive Environment: Immunotherapy Drugs for Neuroblastoma by Manufacturer
3.1 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Manufacturer (2018-2023)
3.2 Global Immunotherapy Drugs for Neuroblastoma Revenue by Manufacturer (2018-2023)
3.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Immunotherapy Drugs for Neuroblastoma by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Immunotherapy Drugs for Neuroblastoma Manufacturer Market Share in 2022
3.4.2 Top 6 Immunotherapy Drugs for Neuroblastoma Manufacturer Market Share in 2022
3.5 Immunotherapy Drugs for Neuroblastoma Market: Overall Company Footprint Analysis
3.5.1 Immunotherapy Drugs for Neuroblastoma Market: Region Footprint
3.5.2 Immunotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
3.5.3 Immunotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Immunotherapy Drugs for Neuroblastoma Market Size by Region
4.1.1 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2029)
4.1.2 Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2029)
4.1.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Region (2018-2029)
4.2 North America Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.3 Europe Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.4 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.5 South America Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.6 Middle East and Africa Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
5.2 Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Type (2018-2029)
5.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
6.2 Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Application (2018-2029)
6.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029)
7 North America
7.1 North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
7.2 North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
7.3 North America Immunotherapy Drugs for Neuroblastoma Market Size by Country
7.3.1 North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
7.3.2 North America Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
8.2 Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
8.3 Europe Immunotherapy Drugs for Neuroblastoma Market Size by Country
8.3.1 Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
8.3.2 Europe Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Market Size by Region
9.3.1 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
10.2 South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
10.3 South America Immunotherapy Drugs for Neuroblastoma Market Size by Country
10.3.1 South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
10.3.2 South America Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Market Size by Country
11.3.1 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Immunotherapy Drugs for Neuroblastoma Market Drivers
12.2 Immunotherapy Drugs for Neuroblastoma Market Restraints
12.3 Immunotherapy Drugs for Neuroblastoma Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Immunotherapy Drugs for Neuroblastoma and Key Manufacturers
13.2 Manufacturing Costs Percentage of Immunotherapy Drugs for Neuroblastoma
13.3 Immunotherapy Drugs for Neuroblastoma Production Process
13.4 Immunotherapy Drugs for Neuroblastoma Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Immunotherapy Drugs for Neuroblastoma Typical Distributors
14.3 Immunotherapy Drugs for Neuroblastoma Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

Published By : GlobalInfoResearch

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock